The “Primary” Antiphospholipid SyndromeRonald A. Asherson, Graham R.V. Hughes, Munther A. Khamashta et al.|Medicine|1989Cited by 963
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesMarie Scully, Samuel J. Machin, Beverley J. Hunt et al.|British Journal of Haematology|2012Cited by 861
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpuraMarie Scully, Samuel J. Machin, Vickie McDonald et al.|Blood|2011Cited by 420
Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trialJ H Scurr, Philip Smith, Samuel J. Machin et al.|The Lancet|2001Cited by 411
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trialHannah Cohen, David Isenberg, Beverley J. Hunt et al.|The Lancet Haematology|2016Cited by 404